André Luiz Pinheiro de Moura

André Luiz Pinheiro de Moura

Auto-generated profile, based on publicly available information

André Luiz Pinheiro de Moura

Department of Pharmacy, Federal University of Piauí, Teresina, Brazil

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2026 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
RSRosilene Ribeiro de Sousa
Rosilene Ribeiro de Sousa
MNMatheus Oliveira Do Nascimento
Matheus Oliveira Do Nascimento
LSLeandro Josual da Costa Santos
Leandro Josual da Costa Santos
FAFrancisco Gesley de Sousa Abreu
Francisco Gesley de Sousa Abreu
AMAndré Luiz Pinheiro de Moura
André Luiz Pinheiro de Moura
ACAndré Carvalho
André Carvalho

8 January 2026 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
RSRosilene Ribeiro de Sousa
Rosilene Ribeiro de Sousa
MNMatheus Oliveira Do Nascimento
Matheus Oliveira Do Nascimento
LSLeandro Josual da Costa Santos
Leandro Josual da Costa Santos
FAFrancisco Gesley de Sousa Abreu
Francisco Gesley de Sousa Abreu
AMAndré Luiz Pinheiro de Moura
André Luiz Pinheiro de Moura
ACAndré Carvalho
André Carvalho

17 February 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
PFPaulo Henrique Fialho
Paulo Henrique Fialho
MNMatheus Nascimento
Matheus Nascimento
BLBeatriz Lira
Beatriz Lira
KFKayo Figueiredo
Kayo Figueiredo
LLLuciano Lopes
Luciano Lopes
ACAndré Carvalho
André Carvalho
To develop and characterize nanostructured formulations of tetracaine and to evaluate their antinociceptive activity in an in vivo model of formalin-induced orofacial pain. Microemulsions of tetracaine (MET) and its gelled version containing 4% chitosan (MEGT) were obtained. The formulations were characterized for particle size, polydispersity index (PDI), zeta potential (ZP), mucoadhesiveness, and in vitro release. In the in vivo study, forty-two female Wistar rats were allocated into seven groups (n = 6): control, eye drops (1% tetracaine + 0.1% phenylephrine), aqueous tetracaine solution (SOCT 1%), microemulsion without tetracaine, microemulsion with tetracaine (MET 1%), gelled microemulsion without tetracaine, and gelled microemulsion with tetracaine (MEGT 1%). Each animal received a topical application of the formulation in the right nostril, followed by a subcutaneous injection of 2% formalin. The formulations exhibited nanometric particle sizes (58.2–161.7 nm), high polydispersity indices (0.50–0.56), and distinct zeta potential values (–41.2 mV for MET and +19.7 mV for MEGT). MEGT showed higher firmness, consistency, and mucoadhesive properties compared to MET. In the release assays, both MET and MEGT provided sustained tetracaine release for up to 6 hours (30.74% and 28.52%, respectively). The tetracaine-containing formulations significantly reduced nociceptive behavior, maintaining low and stable rubbing times, with efficacy comparable to that of the tetracaine + phenylephrine eye drops (p > 0.05). It was possible to develop and characterize nanostructured tetracaine formulations with suitable physicochemical properties, sustained drug release, and effective antinociceptive activity. Both MET and MEGT proved to be promising alternatives to conventional eye drop formulations.

6 October 2026 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Open access
PFPaulo Henrique da Silva Fialho
Paulo Henrique da Silva Fialho
MNMatheus Oliveira Do Nascimento
Matheus Oliveira Do Nascimento
BLBeatriz Santiago de Matos Monteiro Lira
Beatriz Santiago de Matos Monteiro Lira
KFKayo Alves Figueiredo
Kayo Alves Figueiredo
LLLuciano da Silva Lopes
Luciano da Silva Lopes
ACAndré Carvalho
André Carvalho